Mustjoki S - Search Results

1

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.

Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevärn B, Olofsson T, Olsson-Strömberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H; Nordic CML Study Group (NCMLSG). Mustjoki S, et al. Leukemia. 2013 Jul;27(7):1520-6. doi: 10.1038/leu.2013.19. Epub 2013 Jan 18. Leukemia. 2013. PMID: 23328954 Clinical Trial.

2

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia.

Mustjoki S, Lundán T, Knuutila S, Porkka K. Mustjoki S, et al. Leukemia. 2007 Nov;21(11):2363-8. doi: 10.1038/sj.leu.2404807. Epub 2007 Jun 14. Leukemia. 2007. PMID: 17568811 No abstract available.

3

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.

Lundán T, Juvonen V, Mueller MC, Mustjoki S, Lakkala T, Kairisto V, Hochhaus A, Knuutila S, Porkka K. Lundán T, et al. Among authors: mustjoki s. Haematologica. 2008 Feb;93(2):178-85. doi: 10.3324/haematol.11910. Epub 2008 Jan 26. Haematologica. 2008. PMID: 18223279 Free article.

4

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY. Porkka K, et al. Among authors: mustjoki s. Blood. 2008 Aug 15;112(4):1005-12. doi: 10.1182/blood-2008-02-140665. Epub 2008 May 13. Blood. 2008. PMID: 18477770 Free article. Clinical Trial.

5

JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).

Mustjoki S, Borze I, Lasho TL, Alitalo R, Pardanani A, Knuutila S, Juvonen E. Mustjoki S, et al. Leuk Res. 2009 Jan;33(1):54-9. doi: 10.1016/j.leukres.2008.07.008. Epub 2008 Aug 28. Leuk Res. 2009. PMID: 18760472

6

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Mustjoki S, et al. Leukemia. 2009 Aug;23(8):1398-405. doi: 10.1038/leu.2009.46. Epub 2009 Mar 19. Leukemia. 2009. PMID: 19295545

7

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Gruber F, Mustjoki S, Porkka K. Gruber F, et al. Among authors: mustjoki s. Br J Haematol. 2009 Jun;145(5):581-97. doi: 10.1111/j.1365-2141.2009.07666.x. Epub 2009 Apr 15. Br J Haematol. 2009. PMID: 19388927 Free article. Review.

8

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.

Mustjoki S, Rohon P, Rapakko K, Jalkanen S, Koskenvesa P, Lundán T, Porkka K. Mustjoki S, et al. Leukemia. 2010 Jan;24(1):219-22. doi: 10.1038/leu.2009.190. Epub 2009 Sep 24. Leukemia. 2010. PMID: 19776759 No abstract available.

9

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

Mustjoki S, Hernesniemi S, Rauhala A, Kähkönen M, Almqvist A, Lundán T, Porkka K. Mustjoki S, et al. Haematologica. 2009 Oct;94(10):1469-71. doi: 10.3324/haematol.2009.008094. Haematologica. 2009. PMID: 19794096 Free PMC article. No abstract available.

10

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Kreutzman A, et al. Among authors: mustjoki s. Blood. 2010 Aug 5;116(5):772-82. doi: 10.1182/blood-2009-12-256800. Epub 2010 Apr 22. Blood. 2010. PMID: 20413659 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

210 results

Search Page